Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Xilio Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- 0 vs. Q4 2024
- Shares held
- 22.5M
- −3.33M (−12.9%) vs. Q4 2024
- Total value
- $16.3M
- −$8.37M (−33.9%) vs. Q4 2024
- New holders
- 6
- 8 more added
- Sold out
- 6
- 7 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 62 | $45 | 0.00% | −4−6.1% | Reduced |
| Bank of America Corp | 290 | $210 | 0.00% | +25+9.4% | Added |
| Private Wealth Management Group, LLC | 310 | $225 | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $601 | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 3,300 | $2.39K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $7.24K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $7.24K | 0.00% | +10,000 | New |
| Dunhill Financial, LLC | 10,274 | $7.44K | 0.00% | +10,274 | New |
| Steward Partners Investment Advisory, LLC | 20,000 | $14.5K | 0.00% | 00.0% | Unchanged |
| Mariner, LLC | 25,000 | $18.1K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 33,961 | $24.6K | 0.00% | −16,125−32.2% | Reduced |
| ADAR1 Capital Management, LLC | 40,000 | $29.0K | 0.01% | +40,000 | New |
| Scientech Research LLC | 42,546 | $30.8K | 0.01% | +42,546 | New |
| State Street Corp | 43,390 | $31.4K | 0.00% | 00.0% | Unchanged |
| Aptus Capital Advisors, LLC | 46,000 | $33.3K | 0.00% | +5,000+12.2% | Added |
| SevenBridge Financial Group, LLC | 46,000 | $33.6K | 0.01% | +5,000+12.2% | Added |
| Millennium Management LLC | 51,110 | $37.0K | 0.00% | +51,110 | New |
| Northern Trust Corp | 66,609 | $48.3K | 0.00% | +27,401+69.9% | Added |
| Bridgeway Capital Management, LLC | 71,081 | $51.5K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 74,700 | $54.1K | 0.00% | −1,386−1.8% | Reduced |
| Two Sigma Investments, LP | 84,068 | $60.9K | 0.00% | +73,244+676.7% | Added |
| Avantax Planning Partners, Inc. | 150,399 | $108.9K | 0.00% | +150,399 | New |
| UBS Group AG | 163,101 | $118.1K | 0.00% | −86,300−34.6% | Reduced |
| Renaissance Technologies LLC | 177,700 | $128.7K | 0.00% | −118,917−40.1% | Reduced |
| Trustees of Columbia University in the City of New York | 249,635 | $180.7K | 0.03% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 254,346 | $184.2K | 0.00% | −88,884−25.9% | Reduced |
| Geode Capital Management, LLC | 379,016 | $274.6K | 0.00% | +20,594+5.7% | Added |
| AJU IB Investment Co., Ltd. | 667,742 | $483.7K | 0.58% | 00.0% | Unchanged |
| FMR LLC | 884,035 | $640.4K | 0.00% | −511,818−36.7% | Reduced |
| Vanguard Group Inc | 1,135,716 | $822.3K | 0.00% | +233,185+25.8% | Added |
| Morgan Stanley | 1,155,838 | $837.3K | 0.00% | +154,479+15.4% | Added |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.07M | 6.59% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $1.07M | 0.65% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.31M | 0.49% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 9,105,451 | $6.60M | 0.56% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −3,003,259−100.0% | Sold out |
| FIL Ltd | 0 | $0 | 0.00% | −218,705−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −49,093−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −40,316−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,870−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,729−100.0% | Sold out |